The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib trial of durvalumab plus tremelimumab in combination with particle therapy in patients with advanced hepatocellular carcinoma with macrovascular invasion: DEPARTURE trial.
 
Keisuke Koroki
No Relationships to Disclose
 
Sadahisa Ogasawara
Honoraria - Bayer Yakuhin; Chugai Pharma; Eisai; Lilly
Research Funding - AstraZeneca; Bayer Yakuhin; Eisai; Lilly
 
Hirokazu Makishima
No Relationships to Disclose
 
Masaru Wakatsuki
No Relationships to Disclose
 
Asahi Takahashi
No Relationships to Disclose
 
Hiroaki Kanzaki
No Relationships to Disclose
 
Kazufumi Kobayashi
No Relationships to Disclose
 
Masanori Inoue
No Relationships to Disclose
 
Soichiro Kiyono
No Relationships to Disclose
 
Masato Nakamura
No Relationships to Disclose
 
Naoya Kanogawa
No Relationships to Disclose
 
Takayuki Kondo
No Relationships to Disclose
 
Shingo Nakamoto
No Relationships to Disclose
 
Yuki Shiko
No Relationships to Disclose
 
Yoshihito Ozawa
No Relationships to Disclose
 
Yosuke Inaba
No Relationships to Disclose
 
Tomoya Kurokawa
No Relationships to Disclose
 
Hideki Hanaoka
No Relationships to Disclose
 
Shigeru Yamada
No Relationships to Disclose
 
Naoya Kato
Speakers' Bureau - Abbott; Abbvie; Aska Pharmaceutical Co., Ltd.; Astellas Pharma; AstraZeneca Japan; Bayer Yakuhin; Bristol-Myers Squibb Company; Chugai Pharma; Covidien; Daiichi Sankyo Co.,Ltd.; EA Pharma; Eisai; Fujifilm; Gilead Sciences; Kowa; Lilly Japan; Mitsubishi Tanabe Pharma; Miyarisan pharmaceutical; Mochida Pharmaceutical Co. Ltd.; MSD K.K; Mylan; Nichi-iko; Nippon Kayaku; Nobelpharma; Olympus; Ono Pharmaceutical; Otsuka; Shionogi; Sumitomo Dainippon Pharma Co., Ltd.; Takeda; Tsumura & Co.; Zeria Pharmaceutical
Research Funding - Abbvie (Inst); Asahi Kasei (Inst); Asahi Kasei (Inst); Aska Pharmaceutical Co.,Ltd. (Inst); Astellas Pharma (Inst); Boston Scientific (Inst); Chugai Pharma (Inst); Covidien (Inst); CYTLIMIC (Inst); Daiichi Sankyo co.,Ltd. (Inst); EA Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); JIMRO (Inst); Kowa (Inst); Medicos Hirata (Inst); Mitsubishi Tanabe Pharma (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD K.K. (Inst); Nippon Kayaku (Inst); Otsuka (Inst); Shionogi (Inst); Sumitomo Dainippon Pharma Co.,Ltd. (Inst); Takeda (Inst); Tsumura & Co. (Inst)